Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes
EMPA-HEART Cardiolink-6 trial results suggest that the SGLT2 inhibitor is linked to reduced left ventricular mass, a surrogate for reduced heart failure, in patients with CVD and type 2 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

AHA: Mixed Results with Dapagliflozin in T2D Patients
(MedPage Today) -- SGLT2 inhibitor didn't change MACE rate, but did result in other positive CV outcomes (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 10, 2018 Category: Cardiology Source Type: news

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes
The trial did not show a significant reduction in major adverse cardiovascular events but does extend the heart failure benefits of SGLT2 inhibitors to the primary prevention population.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Canagliflozin (Invokana) Gets FDA Nod for CV Protection Canagliflozin (Invokana) Gets FDA Nod for CV Protection
The SGLT2 inhibitor is the first oral diabetes medication approved to reduce the risk of cardiovascular events in patients with type 2 diabetes and heart disease.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 31, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk
Speakers at EASD present divergent risk-benefit analyses for use of SGLT2 inhibitors in type 1 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitor-Amputation Link in Diabetes -- Is it Hypovolemia? SGLT2 Inhibitor-Amputation Link in Diabetes -- Is it Hypovolemia?
Observational study finds an increased amputation risk with diuretic use in people with diabetes, suggesting that the hypovolemic mechanism may also explain the amputation risk seen with canagliflozin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes? DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes?
Top-line data from DECLARE-TIMI 58 hint that CV benefit of the SGLT2 inhibitor dapagliflozin for type 2 diabetes is driven by improvement in heart failure, but 60% of patients were primary prevention.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

EU Okays CV Benefit Labeling for Canagliflozin in Diabetes EU Okays CV Benefit Labeling for Canagliflozin in Diabetes
The European label for the SGLT2 inhibitor canagliflozin for type 2 diabetes will now include positive cardiovascular benefit results from the CANVAS trial, while a decision from the US FDA is forthcoming.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

La FDA advierte acerca de casos poco frecuentes de una infecci ón grave del área genital con los inhibidores del SGLT2 para la diabetes
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 7, 2018 Category: Drugs & Pharmacology Source Type: news

La FDA advierte acerca de casos poco frecuentes de una infecci ó n grave del á rea genital con los inhibidores del SGLT2 para la diabetes
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 7, 2018 Category: Drugs & Pharmacology Source Type: news

FDA: Labeling requirements to add 2m hours to medtech industry ’ s regulatory burden
New FDA labeling regulations submitted to the FDA’s Office of Management and Budget are expected to add an additional approximate 1.6 million hours of work to record keepers at the agency and in the industry, according to an FDA notice The added burden comes from changes to the federal watchdog’s medical device labeling regulations, which the agency is actively seeking comments on. With the changes, the agency expects a burden of approximately 3.3 million hours for itself and 9.2 million hours for third-party disclosures, up approximately 1.6 million hours since the last OMB approval, according to the release. ...
Source: Mass Device - September 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
If you are taking canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or any other sodium-glucose cotransporter-2 (SGLT2) inhibitor, you may want to pay attention to this FDA warning. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

FDA warns of flesh-eating genital infection linked to diabetes drug
The FDA this week warned of serious flesh-eating bacterial infections, or necrotizing fasciitis, reported by patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors intended for treating type 2 diabetes. The federal watchdog said that between March 2013 and May 2018, 12 cases of Fournier’s gangrene, a rare but life-threatening bacterial infection of the tissue under the skin that surrounds muscles, nerves, fat and blood vessels of the perineum, were reported by users of the drug. Read the whole story on our sister site, Drug Delivery Business News The post FDA warns of flesh-eating genital infection linked ...
Source: Mass Device - August 31, 2018 Category: Medical Devices Authors: Fink Densford Tags: Diabetes Food & Drug Administration (FDA) Source Type: news

Flesh-eating infection linked to diabetes drugs that killed one and left 11 others hospitalized
Fournier's gangrene - an infection of the scrotum, the penis, or the perineum - has been linked to SGLT2 inhibitors, which lower blood sugar in adults with type 2 diabetes so far infecting 12 people. (Source: the Mail online | Health)
Source: the Mail online | Health - August 30, 2018 Category: Consumer Health News Source Type: news

FDA Warns of Serious Genital Infection With Diabetes Meds
The FDA is warning about rare cases of necrotizing fasciitis – sometimes called “flesh-eating bacteria” -- of the genitals and genital area in patients taking type 2 diabetes drugs known as SGLT2 inhibitors. (Source: WebMD Health)
Source: WebMD Health - August 30, 2018 Category: Consumer Health News Source Type: news

FDA Warns of Common Diabetes Meds', SGLT2 Inhibitors, Link to Dangerous Genital Infection
THURSDAY, Aug. 30, 2018 -- Rare but serious genital infections, as well as one death, have been reported in some patients taking a certain class of type 2 diabetes medicine, the U.S. Food and Drug Administration says. As a result, the FDA has... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 30, 2018 Category: General Medicine Source Type: news

FDA Warns of Serious Genital Infection With SGLT2 Inhibitors FDA Warns of Serious Genital Infection With SGLT2 Inhibitors
The agency has received reports of 12 cases of necrotizing fasciitis of the perineum in patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors, including five women.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 29, 2018 Category: Drugs & Pharmacology Source Type: news

SGLT2 Inhibitors and Amputations in Diabetes: Still Unclear SGLT2 Inhibitors and Amputations in Diabetes: Still Unclear
Observational study finds increased risk compared with older oral diabetes medications, but class effect question not addressed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Another SGLT2 That You Can Feel Safe Prescribing Another SGLT2 That You Can Feel Safe Prescribing
In regard to amputation risk (and despite a black box warning), it appears that canagliflozin is no less safe than other diabetes drugs.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2018 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news

Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy
Hope that observed renoprotective effects of SGLT2 inhibitors will delay worsening of kidney disease in type 2 diabetes seems to be borne out, as the CREDENCE trial is stopped early.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors: Unreal Primary Prevention? SGLT2 Inhibitors: Unreal Primary Prevention?
These diabetes drugs offer cardiovascular benefits, but only in diabetes patients who already have CV disease, the author argues.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Expert Column Source Type: news

Empagliflozin Eyed for Fatty Liver Disease in Type 2 Diabetes Empagliflozin Eyed for Fatty Liver Disease in Type 2 Diabetes
The first trial of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes and nonalcoholic fatty liver disease indicates the drug might reduce liver fat, but the results of the small study need replication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 22, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Sodium-Glucose Cotransporter 2 Inhibitors: An Overview Sodium-Glucose Cotransporter 2 Inhibitors: An Overview
SGLT2 inhibitors are promising new agents for the treatment of type 2 diabetes, but there are risks to be considered. Which patients would most benefit?U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2018 Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news

Story of Discovery: SGLT2 inhibitors: harnessing the kidneys to help treat diabetes
Research findings lead to the development of a new class of diabetes drugs that allows the kidneys to dispose of excess blood glucose in the urine. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

SGLT2 Inhibitors in Type 1 Diabetes SGLT2 Inhibitors in Type 1 Diabetes
Are SGLT2 inhibitors safe and effective in patients with type 1 diabetes?Medscape Pharmacists (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2018 Category: Consumer Health News Tags: Pharmacist Ask the Expert Source Type: news

Perioperative Considerations Patients With T2DM on SGLT2i Perioperative Considerations Patients With T2DM on SGLT2i
SGLT2 inhibitors create new management challenges for anesthesiologists. What are the unique considerations for diabetic patients taking these agents perioperatively?Anesthesia & Analgesia (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2018 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

SGLT2 Inhibitor-Linked Diabetic Ketoacidosis Is Rare, but Severe SGLT2 Inhibitor-Linked Diabetic Ketoacidosis Is Rare, but Severe
A series of Australian cases of DKA linked to SGLT2 inhibitors confirms the side effect is rare but severe. Most cases had identifiable precipitators.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 21, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

What Cardiologists Need to Know About New Diabetes Drugs What Cardiologists Need to Know About New Diabetes Drugs
Drs O'Donoghue and McGuire discuss the data on the various SGLT2 inhibitors and GLP1 receptor agonists and when to consider prescribing them to your patients with diabetes.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2018 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

FDA Approves Ertugliflozin for Type 2 Diabetes
The FDA has approved the sodium-glucose cotransporter-2 (SGLT2) inhibitor ertugliflozin as an adjunct to diet and exercise for treating adults with type 2... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 22, 2017 Category: Primary Care Source Type: news

FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes
The US Food and Drug Administration has approved ertugliflozin, a fourth SGLT2 inhibitor for use in adults with type 2 diabetes .Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
A U.S. Food and Drug Administration (FDA) safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

SGLT2 Inhibitors as First-line Therapy for Diabetes With CVD? SGLT2 Inhibitors as First-line Therapy for Diabetes With CVD?
An expert argues case for SGLT2 inhibitors as first-line therapy for patients with type 2 diabetes and CVD, but is he fighting a losing battle? As even he concedes cost is currently a major barrier.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

No Signal for Amputation With Empagliflozin in EMPA-REG No Signal for Amputation With Empagliflozin in EMPA-REG
A new paper confirms there is no signal for an increased risk of amputation with the SGLT2 inhibitor empagliflozin among patients with type 2 diabetes and CVD in EMPA-REG.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

New Real-World Analysis Shows INVOKANA ® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 17, 2017 Category: Pharmaceuticals Source Type: news

Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials
In two phase 3 trials, the SGLT2 inhibitor ertugliflozin for the treatment of type 2 diabetes that is uncontrolled with metformin alone or with sitagliptin demonstrated safety and efficacy at 52 weeks.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Halting HF in Patients With Diabetes: Insights From EMPA-REG Halting HF in Patients With Diabetes: Insights From EMPA-REG
A substudy of EMPA-REG finds that SGLT2 inhibitors may slow the onset of heart failure. Dr Pi ñ a discusses the research with study investigator Dr Javed Butler at ESC 2017.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2017 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Another SGLT2 Drug Shines as Insulin Adjunct in T1D (CME/CE)
(MedPage Today) -- Dapagliflozin lowered HbA1c in phase III trial (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 14, 2017 Category: Cardiology Source Type: news

InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes InTandem3: Sotagliflozin Has Benefits and Risks in Type 1 Diabetes
The largest of three phase 3 studies of the novel investigational SGLT1/SGLT2 inhibitor shows that it improves glycemic control and may reduce body weight and BP but also raises some risks, including DKA.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 and DPP-4 Inhibition SGLT2 and DPP-4 Inhibition
What role could combination therapy with these inhibitors play in the management of type 2 diabetes?Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 1, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

AKI Risk with SGLT2 Inibitors? Maybe Not, Clinic Data Show AKI Risk with SGLT2 Inibitors? Maybe Not, Clinic Data Show
Despite FDA warnings of a possible increased risk for AKI with the SGLT2 inhibitors, a new analysis of two large databases finds no evidence of elevated risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Retrospective review of SGLT2 inhibitor exposures reported to 13 poison centers - Schaeffer SE, DesLauriers C, Spiller HA, Aleguas A, Baeza S, Ryan ML.
BACKGROUND: SGLT2 inhibitors are a new class of oral antidiabetics prescribed in the United States since 2013. They act by inhibiting reabsorption of glucose in the proximal convoluted tubule of the kidney, allowing excess glucose to be excreted. Little ha... (Source: SafetyLit)
Source: SafetyLit - August 25, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Do SGLT2 Inhibitors ’ Heart Failure Benefits Involve Sodium-hydrogen Exchanger? Do SGLT2 Inhibitors ’ Heart Failure Benefits Involve Sodium-hydrogen Exchanger?
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may reduce cardiovascular events via interaction with the sodium-hydrogen exchanger, researchers suggest.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine News Source Type: news

Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D
Canagliflozin suppressed the increase in NT-proBNP and high-sensitivity troponin in older patients with type 2 diabetes, which may help shed some light on the beneficial CV effect of SGLT2 inhibitors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Agents Cut CV Events in'Real-World' Analysis
(MedPage Today) -- Scandinavian data show reductions in cardiovascular mortality and HF hospitalizations (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 7, 2017 Category: Cardiology Source Type: news

More Evidence Empagliflozin Protects the Kidneys More Evidence Empagliflozin Protects the Kidneys
New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

New Drug Classes for Diabetes Mean New Options New Drug Classes for Diabetes Mean New Options
Dr Cyrus Desouza reviews GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors, offering advice on which patients may benefit from each class.Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

SGLT1/2 Inhibitor Sotagliflozin'Encouraging' in Type 1 Diabetes SGLT1/2 Inhibitor Sotagliflozin'Encouraging' in Type 1 Diabetes
The investigational, oral agent sotagliflozin, a first-in-class, oral dual inhibitor of both SGLT1 and SGLT2, is in phase 3 trials in type 1 diabetes; results are promising but there are some caveats.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents
Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017. (Source: ConsultantLive)
Source: ConsultantLive - June 14, 2017 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Conferences/ADA 2017 Diabetes Diabetes Type 2 Source Type: news